Translational oncology · 2026
EORTC-1607-GITCG/ABC-09: Open-label first-line, single-arm phase II study of CisGem combined with pembrolizumab in patients with advanced or metastatic biliary tract cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lamarca Angela, Maderer Annett, Wagner Daniel C, McNamara Mairéad G, Bridgewater John A, Arora Arvind, Macarulla Teresa, Adeva Jorge, Hubner Richard A, Lordick Florian, Foerster Friedrich, Weinmann Arndt, Galle Peter R, Leurquin Bryan, Marreaud Sandrine I, Mauer Murielle E, Valle Juan W, Moehler Markus
Аннотация
INTRODUCTION: Immunotherapy recently approved with first-line (1L) chemotherapy for advanced biliary tract cancer (aBTC). Translational research is warranted to identify biomarkers for efficacy.
METHODS: This prospective multicenter non-randomised phase-II study recruited 50 treatment-naïve proven aBTC patients for cisplatin and gemcitabine with pembrolizumab until disease progression or unacceptable toxicity. Primary endpoint was progression-free survival at 6 months (6mPFS, RECIST v.1.1). Secondary endpoints were overall survival (OS), radiological responses and safety. Exploratory translational research was to identify predictive biomarkers. Tumour tissue and blood were collected for MMR, PD-1/PD-L1 in T-cells, monocytes and myeloid derived suppressor cells (MDSCs).
RESULTS: Fifty patients were 38% male, aged 63 (35-84) years. 6mPFS was 61.2% (80% CI 51.7-69.5) with mPFS 8.3 months (95% CI 5.6-10.6); ORR 40.8% (95% CI 27.0-55.8). Med. OS was 13.4 months (95% CI 8.3-20.5) with 24-months-OS 28.4% (95% CI 16.6-41.4). Higher PD-L1 expression correlated with improved PFS (HR=0.59; 95% CI: 0.26-1.37) and OS (HR=0.68; 95% CI: 0.28-1.64). Responders showed higher CD8/Treg ratio than non-responders (26.2% vs 21.2%) and lower CD4/PD1+ and CD8/PD1+ T-cells (33.5% vs 41.5% and 26.4% vs 44.7%) respectively. During treatment, profiling decreased in CD4/PD1+ and CD8/PD1+ Tcells (36.0% vs 22.2% and 41.6% vs 21.0%) respectively. MDSCs increased in non-responders. Responders, CPS-positive and low-stage patients showed normal Neutrophil-Lymphocyte-Ratios.
CONCLUSION: Pembrolizumab plus CisGem showed consistent efficacy to prior phase-III trials. Biomarkers suggest baseline immune landscape influences responses, T-cell exhaustion and immunosuppressive myeloid expansion. Immune phenotyping supports patient selection and further biomarker-driven trials in BTC.
METHODS: This prospective multicenter non-randomised phase-II study recruited 50 treatment-naïve proven aBTC patients for cisplatin and gemcitabine with pembrolizumab until disease progression or unacceptable toxicity. Primary endpoint was progression-free survival at 6 months (6mPFS, RECIST v.1.1). Secondary endpoints were overall survival (OS), radiological responses and safety. Exploratory translational research was to identify predictive biomarkers. Tumour tissue and blood were collected for MMR, PD-1/PD-L1 in T-cells, monocytes and myeloid derived suppressor cells (MDSCs).
RESULTS: Fifty patients were 38% male, aged 63 (35-84) years. 6mPFS was 61.2% (80% CI 51.7-69.5) with mPFS 8.3 months (95% CI 5.6-10.6); ORR 40.8% (95% CI 27.0-55.8). Med. OS was 13.4 months (95% CI 8.3-20.5) with 24-months-OS 28.4% (95% CI 16.6-41.4). Higher PD-L1 expression correlated with improved PFS (HR=0.59; 95% CI: 0.26-1.37) and OS (HR=0.68; 95% CI: 0.28-1.64). Responders showed higher CD8/Treg ratio than non-responders (26.2% vs 21.2%) and lower CD4/PD1+ and CD8/PD1+ T-cells (33.5% vs 41.5% and 26.4% vs 44.7%) respectively. During treatment, profiling decreased in CD4/PD1+ and CD8/PD1+ Tcells (36.0% vs 22.2% and 41.6% vs 21.0%) respectively. MDSCs increased in non-responders. Responders, CPS-positive and low-stage patients showed normal Neutrophil-Lymphocyte-Ratios.
CONCLUSION: Pembrolizumab plus CisGem showed consistent efficacy to prior phase-III trials. Biomarkers suggest baseline immune landscape influences responses, T-cell exhaustion and immunosuppressive myeloid expansion. Immune phenotyping supports patient selection and further biomarker-driven trials in BTC.